Board-certified thoracic oncologist Bruna Pellini, M.D., has been named chief of thoracic medical oncology at Baptist Health Miami Cancer Institute. She specializes in the treatment of patients with lung cancer.
Bruna Pellini, M.D.
Prior to joining Baptist Health, Dr. Pellini was an assistant member of the Department of Thoracic Oncology at Moffitt Cancer Center and Research Institute and an assistant professor of oncology at the Morsani College of Medicine at the University of South Florida in Tampa.
“We are proud to welcome Dr. Pellini to our highly skilled team of cancer care specialists, dedicated to providing the highest quality care,” said Leonard Kalman, M.D., executive deputy medical director and chief medical officer at Miami Cancer Institute. “She brings an unparalleled level of expertise that will benefit patients by elevating the standard of treatment, improving outcomes and enhancing their experience.”
Dr. Pellini earned her medical degree at Universidade Federal do Rio Grande do Sul in Brazil. She completed her internal medicine residency at the University of Central Florida College of Medicine in Orlando and went on to pursue a medical oncology fellowship at Washington University School of Medicine in St. Louis.
Dr. Pellini is actively involved in translational research and clinical trials in thoracic oncology. Her research focuses on the integration of liquid biopsy technologies to improve cancer care, enabling real-time, non-invasive monitoring of treatment response, earlier detection of recurrence and personalization of therapy for patients with lung cancer.
Dr. Pellini has authored more than 40 peer-reviewed publications in high-impact journals, including the Journal of Clinical Oncology and Clinical Cancer Research, and has presented her work at major national and international oncology conferences such as the American Society of Clinical Oncology (ASCO) and the International Association for the Study of Lung Cancer. She has experience leading and developing investigator-initiated and multicenter clinical trials.
In addition to her research and clinical work, Dr. Pellini contributes to the oncology community through service on the editorial boards of JCO Oncology Advances and The Journal of Liquid Biopsy. She is also a reviewer for several leading journals in the field.
On a national level, Dr. Pellini is the co-chair of the National Institutes of Health Liquid Biopsy Scientific Interest Group and a member of the Southwest Oncology Group (SWOG) Lung Translational Medicine Subcommittee. She is also the translational chair of the SWOG INSIGHT Phase III trial in early-stage non-small cell lung cancer (NCT06498635). She serves on the ASCO Stage IV NSCLC Living Guidelines Panel, the ASCO Scientific Committee for Metastatic Non-Small Cell Lung Cancer and the International Society for Liquid Biopsy Education and Membership Committees.
Dr. Pellini’s care philosophy centers on partnership, purpose and clarity. “I believe patients deserve compassion, honesty and a clear plan they can trust,” she said. “I approach each patient as a whole person, not a diagnosis, and strive to combine cutting-edge science with active listening and shared decision-making. My goal is to guide patients through complex moments with expertise, transparency and unwavering support.”
Dr. Pellini is fluent in English and Portuguese and conversational in Spanish. She will see patients at Miami Cancer Institute, located at 8900 North Kendall Drive, Miami, Florida.
